BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Piccicacco N, Zeitler K, Ing A, Montero J, Faughn J, Silbert S, Kim K. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. J Antimicrob Chemother 2022:dkac256. [PMID: 35913836 DOI: 10.1093/jac/dkac256] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Smirnova OA, Ivanova ON, Fedyakina IT, Yusubalieva GM, Baklaushev VP, Yanvarev DV, Kechko OI, Mitkevich VA, Vorobiev PO, Fedorov VS, Bartosch B, Valuev-elliston VT, Lipatova AL, Ivanov AV. SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines. Cancers 2023;15:632. [DOI: 10.3390/cancers15030632] [Reference Citation Analysis]
2 Scotto R, Buonomo AR, Iuliano A, Foggia M, Sardanelli A, Villari R, Pinchera B, Gentile I, Federico II COVID-Team. Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study. Vaccines 2023;11:200. [DOI: 10.3390/vaccines11020200] [Reference Citation Analysis]
3 Rasmussen LD, Lebech AM, Øvrehus A, Poulsen BK, Christensen HR, Nielsen H, Johansen IS, Omland LH, Wiese L, Helleberg M, Storgaard M, Dalager-Pedersen M, Rasmussen TA, Benfield T, Petersen TS, Andersen ÅB, Gram MA, Stegger M, Edslev SM, Obel N. Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark. Br J Clin Pharmacol 2022. [PMID: 36519217 DOI: 10.1111/bcp.15644] [Reference Citation Analysis]
4 De Vito A, Colpani A, Saderi L, Puci M, Zauli B, Fiore V, Fois M, Meloni MC, Bitti A, Di Castri C, Maida I, Babudieri S, Sotgiu G, Madeddu G. Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression. Viruses 2022;15. [PMID: 36680111 DOI: 10.3390/v15010071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Farhadian N, Farhadian M, Zamanian MH, Taghadosi M, Vaziri S. Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis. Immunopharmacology and Immunotoxicology 2022. [DOI: 10.1080/08923973.2022.2160733] [Reference Citation Analysis]
6 Woo MS, Brehm TT, Fischer M, Heyer A, Wichmann D, Jordan S, Nörz D, Lütgehetmann M, Addo MM, Lohse AW, Schmiedel S, Kluge S, Schulze zur Wiesch J. Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study. Microbiol Spectr 2022. [DOI: 10.1128/spectrum.04103-22] [Reference Citation Analysis]
7 Jing H, Wu X, Xiang M, Liu L, Novakovic VA, Shi J. Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.992384] [Reference Citation Analysis]
8 Amani B, Amani B. Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis. Rev Med Virol 2022;32:e2402. [PMID: 36226323 DOI: 10.1002/rmv.2402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]